Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
This study has been completed.
Study NCT00028002 Information provided by National Cancer Institute (NCI)
First Received: December 7, 2001 Last Updated: September 15, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastrointestinal Stromal Tumor
Additional conditions recognized in this trial
Gastrointestinal Stromal Tumors
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Interventions listed in this trial
imatinib mesylate
adjuvant therapy
conventional surgery
neoadjuvant therapy
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
American College of Radiology Imaging Network
Eastern Cooperative Oncology Group
Back to top of Main Content
